Selnoflast was well tolerated and achieved the plasma and tissue exposure predicted to inhibit NLRP3. Expression of IL-1β gene signature in sigmoidal tissue biopsies, single-cell RNA sequencing and additional biomarker analyses showed no robust differences between the two treatment arms, suggesting that targeting the NLRP3 inflammasome with selnoflast may be of limited therapeutic benefit to reduce inflammation in UC.
德陽思諾生物科技有限公司
聯(lián)系商家時請?zhí)峒癱hemicalbook，有助于交易順利完成！
思諾生物
<bdo id="zxil9"></bdo>